Amarin Corp Plc (AMRN)

[couldbebetter]

If generics win the stock would react until someone figures out that
the generics would have to produce a product essentially the same as
Vascepa. Maybe they would run into a problem in attempting to do that.
Should the generics launch a product then Vascepa in the US is done.
What I would hope management would do at that point is find a buyer
based mainly on the value of Vascepa for Europe which will have about
11 years free of generics, regardless of what the courts in the US
decide. My opinion is Europe is worth more than the US. Then, there
is the rest of the world which has value. Without the US my opinion is
that the takeout value of AMRN would be around $10-$20 billion as I
believe AMRN (or its acquirer) would be able to receive $2000 per
patient in revenues with 2-6 million patients (just for Europe)
likely.